In these patients with secondary high-grade gliomas the most recurrent genetic alterations were BRAFV600E mutation and CDKN2A deletion: in the large majority of cases these mutations could be traced back to the corresponding low-grade glioma [143]. The gene discussed is CDKN2A; the disease is central nervous system cancer.